• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Relationship between CD4+ T-cell counts/HIV-1 RNA plasma viral load and AIDS-defining events among persons followed in the ACTG longitudinal linked randomized trials study.在 ACTG 纵向链接随机试验研究中随访的人群中,CD4+T 细胞计数/艾滋病毒-1 RNA 血浆病毒载量与艾滋病定义事件之间的关系。
J Acquir Immune Defic Syndr. 2010 Sep;55(1):117-27. doi: 10.1097/QAI.0b013e3181e8c129.
2
Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team.除了监测 CD4+ 淋巴细胞计数外,监测血浆 HIV-1 RNA 水平可改善对抗逆转录病毒治疗反应的评估。艾滋病临床试验组 241 方案病毒学子研究团队。
Ann Intern Med. 1997 Jun 15;126(12):929-38. doi: 10.7326/0003-4819-126-12-199706150-00001.
3
Higher risk of AIDS or death in patients with lower CD4 cell counts after virally suppressive HAART.病毒抑制性高效抗逆转录病毒治疗后 CD4 细胞计数较低的患者 AIDS 或死亡风险较高。
HIV Med. 2009 Nov;10(10):657-60. doi: 10.1111/j.1468-1293.2009.00739.x. Epub 2009 Jul 9.
4
Short-term risk for AIDS-indicator diseases predicted by plasma HIV-1 RNA and CD4+ lymphocytes.由血浆HIV-1 RNA和CD4 +淋巴细胞预测的艾滋病指标疾病的短期风险。
Scand J Infect Dis. 1999;31(1):37-42. doi: 10.1080/00365549950161862.
5
The effect of opportunistic illness on HIV RNA viral load and CD4+ T cell count among HIV-positive adults taking antiretroviral therapy.机会性感染对接受抗逆转录病毒治疗的 HIV 阳性成年人的 HIV RNA 病毒载量和 CD4+T 细胞计数的影响。
J Int AIDS Soc. 2013 Apr 1;16(1):17355. doi: 10.7448/IAS.16.1.17355.
6
Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults. Abacavir Phase 2 Clinical Team.阿巴卡韦单药及与齐多夫定联合用药在HIV感染成人中的抗逆转录病毒作用及安全性。阿巴卡韦2期临床研究团队。
AIDS. 1998 Nov 12;12(16):F203-9. doi: 10.1097/00002030-199816000-00002.
7
Association of CD4+ T-cell Count, HIV-1 RNA Viral Load, and Antiretroviral Therapy With Kaposi Sarcoma Risk Among HIV-infected Persons in the United States and Canada.美国和加拿大HIV感染者中CD4+ T细胞计数、HIV-1 RNA病毒载量及抗逆转录病毒治疗与卡波西肉瘤风险的关联
J Acquir Immune Defic Syndr. 2017 Aug 1;75(4):382-390. doi: 10.1097/QAI.0000000000001394.
8
The prognostic importance of changes in CD4+ cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy.启动高效抗逆转录病毒治疗后女性CD4+细胞计数和HIV-1 RNA水平变化的预后重要性。
Ann Intern Med. 2004 Feb 17;140(4):256-64. doi: 10.7326/0003-4819-140-4-200402170-00007.
9
Maintaining antiretroviral therapy reduces the risk of AIDS-defining events in patients with uncontrolled viral replication and profound immunodeficiency.维持抗逆转录病毒疗法可降低病毒复制未得到控制且存在严重免疫缺陷的患者发生艾滋病界定事件的风险。
Clin Infect Dis. 2008 Jan 15;46(2):296-304. doi: 10.1086/524753.
10
CD4+ T-cell percentage is an independent predictor of clinical progression in AIDS-free antiretroviral-naive patients with CD4+ T-cell counts >200 cells/mm3.在CD4+ T细胞计数>200个细胞/mm3且未接受过抗逆转录病毒治疗的无艾滋病患者中,CD4+ T细胞百分比是临床进展的独立预测指标。
Antivir Ther. 2009;14(3):451-7. doi: 10.1177/135965350901400311.

引用本文的文献

1
CD24-Fc resolves inflammation and enhances anti-HIV CD8 T cells with polyfunctionality during HIV-1 infection under cART.在抗逆转录病毒疗法(cART)下的HIV-1感染期间,CD24-Fc可缓解炎症并增强具有多功能性的抗HIV CD8 T细胞。
PLoS Pathog. 2025 Aug 8;21(8):e1012826. doi: 10.1371/journal.ppat.1012826. eCollection 2025 Aug.
2
CD24-Fc resolves inflammation and rescues CD8 T cells with polyfunctionality in humanized mice infected with HIV-1 under cART.CD24-Fc可缓解炎症,并在接受抗逆转录病毒治疗(cART)的感染HIV-1的人源化小鼠中挽救具有多功能性的CD8 T细胞。
bioRxiv. 2024 Dec 19:2024.12.16.628615. doi: 10.1101/2024.12.16.628615.
3
Empowerment and utilization of HIV testing among partnered women in Zambia: Evidence from the Zambia demographic and health survey 2018.赞比亚已婚女性中艾滋病毒检测的赋权与利用:来自2018年赞比亚人口与健康调查的证据
PLOS Glob Public Health. 2024 Dec 12;4(12):e0002791. doi: 10.1371/journal.pgph.0002791. eCollection 2024.
4
Empowering adolescents living with perinatally-acquired HIV: tailored CD4+ count assessment for optimized care, the EDCTP READY-study.增强围产期感染艾滋病毒青少年的能力:为优化治疗量身定制的CD4+细胞计数评估,即EDCTP READY研究。
Front Med (Lausanne). 2024 Sep 20;11:1457501. doi: 10.3389/fmed.2024.1457501. eCollection 2024.
5
A Comprehensive Approach to Assuring Quality of Laboratory Testing in HIV Surveys: Lessons Learned From the Population-Based HIV Impact Assessment Project.一种全面的方法来确保 HIV 监测中实验室检测的质量:从基于人群的 HIV 影响评估项目中吸取的经验教训。
J Acquir Immune Defic Syndr. 2021 Aug 1;87(Suppl 1):S17-S27. doi: 10.1097/QAI.0000000000002702.
6
Cerebral Toxoplasmosis, CMV and Bacterial Pneumonia with Decreasing CD4+ T-Cell Count as Results of Antiretroviral Therapy Discontinuation-A Case Report.因停用抗逆转录病毒疗法导致 CD4+ T 细胞计数下降并发脑弓形虫病、巨细胞病毒感染和细菌性肺炎——病例报告
Pathogens. 2021 Apr 20;10(4):497. doi: 10.3390/pathogens10040497.
7
Women's Empowerment and HIV Testing Uptake: A Meta-analysis of Demographic and Health Surveys from 33 Sub-Saharan African Countries.妇女赋权与艾滋病毒检测接受情况:对撒哈拉以南非洲33个国家人口与健康调查的荟萃分析
Int J MCH AIDS. 2020;9(3):274-286. doi: 10.21106/ijma.372. Epub 2020 Jul 23.
8
Effect of AIDS-defining events at initiation of antiretroviral therapy on long-term mortality of HIV/AIDS patients in Southwestern China: a retrospective cohort study.中国西南部地区抗逆转录病毒治疗起始时艾滋病定义事件对HIV/AIDS患者长期死亡率的影响:一项回顾性队列研究
AIDS Res Ther. 2020 Jul 17;17(1):44. doi: 10.1186/s12981-020-00300-4.
9
A Multi-State Model Examining Patterns of Transitioning Among States of Engagement in Care in HIV-Positive Individuals Initiating Combination Antiretroviral Therapy.一个多状态模型,用于研究开始联合抗逆转录病毒治疗的HIV阳性个体在护理参与状态之间的转变模式。
J Acquir Immune Defic Syndr. 2016 Dec 15;73(5):531-539. doi: 10.1097/QAI.0000000000001109.
10
The impact of age on the prognostic capacity of CD8+ T-cell activation during suppressive antiretroviral therapy.年龄对抑制性抗逆转录病毒治疗期间 CD8+ T 细胞激活的预后能力的影响。
AIDS. 2013 Aug 24;27(13):2101-10. doi: 10.1097/QAD.0b013e32836191b1.

本文引用的文献

1
Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV.与成人 HIV 感染者的非致命性 AIDS 和严重非 AIDS 事件相关的全因死亡率风险。
AIDS. 2010 Mar 13;24(5):697-706. doi: 10.1097/QAD.0b013e3283365356.
2
Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.HIV暴露儿童和HIV感染儿童机会性感染的预防与治疗指南:美国疾病控制与预防中心、国立卫生研究院、美国传染病学会HIV医学协会、儿科传染病学会及美国儿科学会的建议
MMWR Recomm Rep. 2009 Sep 4;58(RR-11):1-166.
3
Nonadherence to primary prophylaxis against Pneumocystis jirovecii pneumonia.未坚持对耶氏肺孢子菌肺炎进行一级预防。
PLoS One. 2009;4(3):e5002. doi: 10.1371/journal.pone.0005002. Epub 2009 Mar 25.
4
HIV-associated opportunistic infections--going, going, but not gone: the continued need for prevention and treatment guidelines.与艾滋病病毒相关的机会性感染——持续存在:对预防和治疗指南仍有需求
Clin Infect Dis. 2009 Mar 1;48(5):609-11. doi: 10.1086/596756.
5
Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384.在艾滋病临床试验组方案384中,联合抗逆转录病毒疗法下T细胞亚群的不完全重建。
Clin Infect Dis. 2009 Feb 1;48(3):350-61. doi: 10.1086/595888.
6
Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20-year cohort study.艾滋病毒感染者癌症发病率趋势及抗逆转录病毒疗法的影响:一项为期20年的队列研究。
AIDS. 2009 Jan 2;23(1):41-50. doi: 10.1097/QAD.0b013e328317cc2d.
7
AIDS clinical trials group longitudinal linked randomized trials (ALLRT): rationale, design, and baseline characteristics.艾滋病临床试验组纵向关联随机试验(ALLRT):原理、设计与基线特征
HIV Clin Trials. 2008 Jul-Aug;9(4):269-82. doi: 10.1310/hct0904-269.
8
Rates of hospitalizations and associated diagnoses in a large multisite cohort of HIV patients in the United States, 1994-2005.1994 - 2005年美国大型多中心HIV患者队列中的住院率及相关诊断情况
AIDS. 2008 Jul 11;22(11):1345-54. doi: 10.1097/QAD.0b013e328304b38b.
9
CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection.HIV感染初始治疗后的CD4+计数与非艾滋病疾病风险
AIDS. 2008 Apr 23;22(7):841-8. doi: 10.1097/QAD.0b013e3282f7cb76.
10
Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3.开始接受高效抗逆转录病毒治疗(HAART)且CD4 + T细胞计数≥200个细胞/立方毫米的HIV-1阳性患者临床进展的预测因素。
Antivir Ther. 2007;12(6):941-7.

在 ACTG 纵向链接随机试验研究中随访的人群中,CD4+T 细胞计数/艾滋病毒-1 RNA 血浆病毒载量与艾滋病定义事件之间的关系。

Relationship between CD4+ T-cell counts/HIV-1 RNA plasma viral load and AIDS-defining events among persons followed in the ACTG longitudinal linked randomized trials study.

机构信息

Department of Biostatistics, Harvard School of Public Health, Boston, MA, USA.

出版信息

J Acquir Immune Defic Syndr. 2010 Sep;55(1):117-27. doi: 10.1097/QAI.0b013e3181e8c129.

DOI:10.1097/QAI.0b013e3181e8c129
PMID:20622677
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2927805/
Abstract

BACKGROUND

AIDS-defining events (ADEs) decreased in the era of highly active antiretroviral therapy but still lead to hospitalizations and deaths. Understanding factors related to ADEs is important to mitigate events.

METHODS

We examined the relationship between demographics, behaviors, comorbidities, laboratory, clinical measurements, and ADEs diagnosed among subjects randomized to antiretroviral treatments (ART)/strategies and followed prospectively. Logistic regression models using generalized estimating equations generated odds ratios (ORs) focusing on the relationship between current CD4 T-cell count (CD4)/HIV-1 RNA viral load (VL) and ADEs in the subsequent 16-week study period.

RESULTS

Among the 2948 subjects in the analysis, overall incidence of ADEs was 1.53 per 100 person-years. Multivariate regression models adjusted for demographics, body mass index, and ADE history. A 6-level time-varying variable examined VL (>100,000 copies/mL, < or =100,000) at CD4 levels (0-50, 51-200, >200 cells/microL); reference level was CD4 >200/VL < or =100,000. Among ART naives, odds of having an ADE in the subsequent 16-week interval were greater among subjects with lower CD4 counts; this relationship was modified by VL level (CD4 < or =50/VL >100,000: OR 37.2; CD4 < or =50/VL < or =100,000: OR 30.5; CD4 51-200/VL >100,000: OR 13.0; CD4 51-200/VL < or =100,000: OR 4.5; all P values <0.001). Similar results were seen among ART-experienced subjects.

CONCLUSIONS

Recent CD4 and VL values are closely associated with development of ADEs even after examining a multitude of potential factors.

摘要

背景

在高效抗逆转录病毒治疗时代,艾滋病定义性事件(ADEs)有所减少,但仍导致住院和死亡。了解与 ADEs 相关的因素对于减轻事件至关重要。

方法

我们研究了接受抗逆转录病毒治疗(ART)/策略随机分组并前瞻性随访的受试者中,人口统计学、行为、合并症、实验室、临床测量值与诊断为 ADEs 之间的关系。使用广义估计方程的逻辑回归模型生成关注 CD4 T 细胞计数(CD4)/HIV-1 RNA 病毒载量(VL)与后续 16 周研究期间 ADEs 之间关系的比值比(ORs)。

结果

在分析的 2948 名受试者中,ADEs 的总发生率为 1.53/100 人年。多变量回归模型调整了人口统计学、体重指数和 ADE 史。一个 6 级时变变量检查了 CD4 水平(0-50、51-200、>200 个细胞/微升)时的 VL(>100,000 拷贝/mL、≤100,000);参考水平为 CD4>200/VL≤100,000。在 ART 初治者中,在随后的 16 周间隔内发生 ADE 的可能性在 CD4 计数较低的患者中更高;这种关系受到 VL 水平的修饰(CD4≤50/VL>100,000:OR 37.2;CD4≤50/VL≤100,000:OR 30.5;CD4 51-200/VL>100,000:OR 13.0;CD4 51-200/VL≤100,000:OR 4.5;所有 P 值均<0.001)。在 ART 经验丰富的受试者中也观察到了类似的结果。

结论

即使在检查了多种潜在因素后,最近的 CD4 和 VL 值与 ADEs 的发生密切相关。